|
|
| 1. |
Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease
John C. Adair, MD; Janice E. Knoefel, MD; and Nancy Morgan, RPh Neurology. 2001;57:1515-1517.
|
| 2. |
Clinical Applications of N-acetylcysteine
Gregory S. Kelly, N.D.
Alt Med Rev 1998;3(2):114-127
http://www.thorne.com/pdf/journal/3-2/n_acetylcysteine.pdf
|
| 3. |
Co-administration of N-acetylcysteine, vitamin B12 and folate in cognitively impaired hyperhomocysteinaemic patients.
McCaddon A, Davies G.
International Journal of Geriatric Psychiatry. 2005;20(10):998-1000.
|
| 4. |
N-acetylcysteine treatment lowers plasma homocysteine but not serum lipoprotein(a) levels
Olov Wiklund, Gunnar Fager, Anders Andersson, Ulf Lundstam, Parvesh Masson, Bjiirn Hultberg
Atherosclerosis 119 (1996) 99-106
|
| 5. |
Congeners Of NGAMMA-Acetyl-L-Cysteine But Not Aminoguanidine Act As Neuroprotectants From The Lipid Peroxidation Product 4-Hydroxy-2-Nonenal
M. Diana Neely, Lisa Zimmerman, Matthew J. Picklo, Joyce J. Ou, Catha R. Morales, Kathleen S. Montine, Venkataraman Amaranth, and Thomas J. Montine
Free Radical Biology & Medicine, Vol. 29, No. 10, pp. 1028-1036, 2000
|
| 6. |
Urinary and Plasma Homocysteine and Cysteine Levels during Prolonged Oral N-acetylcysteine Therapy
Paolo Ventura, Rossana Paninib, Gianluca Abbatia, Germano Marchettia, and Gianfranco Salviolib
Pharmacology. 2003;68(2):105-14
|
|
|
